Edgar Filing: NEKTAR THERAPEUTICS - Form 4/A

NEKTAR TI	HERAPEUTICS								
Form 4/A									
January 15, 2	2016								
FORM	14 UNITED	STATES		RITIES A shington			E COMMISSION		PPROVAL 3235-0287
Check thi if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	6. r Filed pur inue.	suant to S a) of the F	CHAN ection 1 Public U	IGES IN SECUE	BENEF RITIES ne Securit ding Cor	ICIAL O ies Excha npany Ac	WNERSHIP OF ange Act of 1934, t of 1935 or Sectio 1940	Expires: Estimated burden hou response	urs per
(Print or Type F	Responses)								
1. Name and A Gergel Ivan	ddress of Reporting P.		Symbol	er Name and AR THER		-	5. Relationship o Issuer (Che	f Reporting Per ck all applicabl	
(Mo			below)			Officer (giv below)	ve title 10% Owner below) Chief Medical Officer		
			endment, Da nth/Day/Yea 2015	-	1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securities .	Acquired, Disposed o	of, or Beneficia	lly Owned
	2. Transaction Date (Month/Day/Year)		ed Date, if	3.	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerce Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	<u>(1)</u>	12/15/2015		А	15,000	(2)	12/14/2023	Common Stock	15,000
Stock Option	\$ 15.55	12/15/2015		А	12,500	(3)	12/14/2023	Common Stock	12,500

Edgar Filing: NEKTAR THERAPEUTICS - Form 4/A

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Gergel Ivan P. C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO, CA 94158			SVP & Chief Medical Officer			
Signatures						

Gil M. Labrucherie,	01/15/2016
Attorney-in-Fact	01/13/2010

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.
- (2) This restricted stock unit vests over 3 years in equal quarterly installments.
- (3) This stock option vests in equal monthly installments over the 4-year period following the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.